Sotorasib: First Approval
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Surprisingly, in 2021, after unremitting efforts, a milestone was achieved: the KRASG12C inhibitor sotorasib was approved by the FDA for a specific subgroup of patients with non-small cell lung cancer (NSCLC),10”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [10]
In the citing paper
“In recent years, two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved by the United States Food and Drug Administration (US FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), 8,9 but not in mCRC as monotherapy as to date.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R. R., & O’Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 156
Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.321 · Cited by 30
Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9003 · Cited by 24 · cited 1×
“The clinical benefit of sotorasib was also seen regardless of age (< 65 vs ≥ 65 years), ECOG PS (0 vs 1), metastatic disease (yes vs no), prior lines of therapy (1 vs ≥ 2), prior anti-PD-1/PD-L1 therapy (yes vs no), TP53 co-mutation (wild-type vs mutant), STK11 comutation (wild-type vs mutant), KEAP1 co-mutation (wild…”
BackgroundReck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1730 · Cited by 21
Saiki, A. Y., Gaida, K., Rex, K., Achanta, P., Miguel, T. S., Koppada, N., Bagal, D., Lanman, B. A., Foti, R. S., McCarter, J. D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4484 · Cited by 15
Spira, A. I., Wilson, F. H., Shapiro, G. I., Dooms, C., Fontecedro, A. C., Esaki, T., Barlési, F., Cocks, K., Trigg, A., Stevinson, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9057 · Cited by 13
Hong, D. S., Strickler, J. H., Fakih, M., Falchook, G. S., Li, B. T., Durm, G. A., Burns, T. F., Ramalingam, S. S., Goldberg, S. B., Frank, R. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps2669 · Cited by 10
Research works printed but not linked: 9
- Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.
- Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.
- Amgen. FDA grants sotorasib priority review designation for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer [media release]. 16 Feb 2021. https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.
- Cardona P Simiens M Purkis J An open-label study to evaluate the effect of omeprazole on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-009] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of single and multiple doses of rifampin on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-010] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Vuu I Simiens M Purkis J A phase I, open-label study to evaluate drug-drug interactions between metformin and sotorasib (AMG 510) in healthy subjects [abstract no. PIII-018] Clin Pharmacol Ther 2021 109 Suppl. 1 S50
- Cardona P Spring M Purkis J An open-label study to evaluate the effect of sotorasib (AMG 510) on digoxin pharmacokinetics in healthy subjects [abstract no. PII-011] Clin Pharmacol Ther 2021 109 Suppl. 1 S31
- Guardant Health. Guardant360® CDx receives FDA approval as first and only liquid biopsy companion diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C inhibitor for use in advanced non-small cell lung cancer [media release]. 28 May 2021. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx.
- QIAGEN. QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer [media release]. 28 May 2021. https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Launches-First-FDA-approved-Tissue-Companion-Diagnostic-to-Identify-the-KRAS-G12C-Mutation-in-NSCLC-Tumours-and-Expand-Precision-Medicine-Options-in-Lung-Cancer/default.aspx.
Cited by
Items 101–200 of 267
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“On the basis of these studies, Sotorasib was granted FDA-approval, but only for KRASMT lung cancer patients (36).”
MethodZalli, D., Mai, Z., Ferati, E., Ramaj, A., Bregu, R., & Pranjol, M. Z. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_413-1 · Cited by 12
PROTACs coupled with oligonucleotides to tackle the undruggable
Zhang, G., Yan, S., Liu, Y., Du, Z., Min, Q., & Qin, S. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2459528 · Cited by 12
Kumar, V., Meenu, Shaquiquzzaman, M., Alam, M. A., Akhter, M., Parveen, D., Kaleem, M., Charan, S., Saifullah, M. K., & Tasneem, S. (2026) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2026.110527 · Cited by 12
Fast fragment and compound screening pipeline at the Swiss Light Source
Stegmann, D. P., Steuber, J., Fritz, G., Wojdyla, J. A., & Sharpe, M. E. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.08.005 · Cited by 12
Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications
Rekha, T. N., & Mohammed, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116441 · Cited by 14
Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy
Yin, G., Lv, G., Zhang, J., Jiang, H., Lai, T., Yang, Y., Ren, Y., Wang, J., Yi, C., Chen, H., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108110 · Cited by 11
N-Heterocycles as Privileged Scaffolds in FDA Approved Different NMEs of 2021: A Review
Chaudhry, F., Munir, R., & Malik, N. (2022) · Letters in Organic Chemistry · doi:10.2174/1570178620666221026095145 · Cited by 11
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 11
Oliveira, R. J. D. S., Gomes, I. N. F., da Silva, L. S., Lengert, A. V. H., Laus, A. C., Melendez, M. E., Munari, C. C., Cury, F. D. P., Longato, G. B., & Reis, R. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147774 · Cited by 11
“The oncoprotein KRAS was for decades considered an “undruggable” target, and recently, sotorasib (AMG510) was approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with specific KRAS G12C-mutated locally advanced or metastatic NSCLC [19].”
BackgroundKalariya, R. N., Ojha, D., Rana, S., Rode, A. B., Bhosale, R. S., & Yadav, J. S. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.100954 · Cited by 10
KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma
Deng, M., Guo, J., Ling, Z., Zhang, C., He, L., Fan, Z., Cheng, B., & Xia, J. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23563 · Cited by 10
Iska, S., & Alley, E. W. (2023) · Case Reports in Oncology · doi:10.1159/000529828 · Cited by 10
Chen, W., Li, L., Cheng, S., & Yu, J. (2022) · Disease Markers · doi:10.1155/2022/2631852 · Cited by 10
“Although the successful use and marketing of small molecule inhibitors targeting the KRAS-G12C mutation in clinical trials has demonstrated that KRAS mutations can be successfully targeted, they are not yet used on a large scale in all countries [7, 8].”
BackgroundOptimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
Lim, J. U., Negrao, M. V., & Hong, D. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-115849 · Cited by 9
Tajiknia, V., Pinho-Schwermann, M. P., Srinivasan, P. R., Borrero, L. J. H., Zhang, L., Huntington, K. E., & El‐Deiry, W. S. (2024) · American Journal of Cancer Research · doi:10.62347/dvxl1377 · Cited by 9
Wang, X., Zhu, J., Li, L., Zhao, Q., Huang, Y., Wen, C., Chen, D., & Wu, L. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00934-4 · Cited by 9
“Sotorasib is a novel KRAS-G12C inhibitor, and approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy (Blair 2021).”
BackgroundAdagrasib in the treatment of colorectal cancer
Haddad, S. F., Bouferraa, Y., & Nair, K. G. (2025) · Future Oncology · doi:10.1080/14796694.2025.2524311 · Cited by 10
“Sotorasib is a first-in-class direct selective mutated KRAS G12C inhibitor developed by Amgen [23].”
Huo, Q., Li, K., Sun, X., Zhuang, A., Minami, K., Tamari, K., Ogawa, K., Fishel, M. L., Li, B., & Yokota, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-41835-6 · Cited by 9
Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025) · Biomolecules · doi:10.3390/biom15091316 · Cited by 8
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 8
Tiz, D. B. (2026) · Medicines · doi:10.3390/medicines13030022 · Cited by 8
Zhu, Y.-N., Tang, M. X., Sun, K.-X., Gao, B., Shi, X.-P., & Zhang, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1348688 · Cited by 8
“In 2021, sotorasib was approved by the Food and Drug Administration (FDA), becoming the world ’ s fi rst drug speci fi cally for the treatment of locally advanced or metastatic NSCLC with KRAS G12C mutation (Blair, 2021).”
MethodLam, L. K. M., Tien, T., Wildung, M. R., White, L. A., Sellon, R. K., Fidel, J. L., & Shelden, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273705 · Cited by 8
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8
Gorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J. M., Crcarevska, M. S., Dodov, M. G., Geškovski, N., & Goračinova, K. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.23 · Cited by 8
Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions
Han, D., Li, A., Zhu, L., Zhuang, C., Zhao, Q., & Zou, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116878 · Cited by 7
Prajapati, V., Singh, A. K., Kumar, A. M., Singh, H., Pathak, P., Grishina, M., Kumar, V., Khalilullah, H., Verma, A., & Kumar, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00923a · Cited by 7
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 7
Durojaye, O. A., Uzoeto, H. O., Okoro, N. O., Cosmas, S., Fadahunsi, A. A., Bellah, S. F., Odiba, A. S., & Nwanguma, B. C. (2025) · Medical Oncology · doi:10.1007/s12032-025-02936-6 · Cited by 8
An In Vivo Inflammatory Loop Potentiates KRAS Blockade
Arendt, K. A. M., Ntaliarda, G., Armenis, V., Kati, D., Henning, C., Giotopoulou, G. A., Pepe, M. A. A., Klotz, L. V., Lamort, A., Hatz, R. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030592 · Cited by 7
“Despite coordinated efforts [1], anti-KRAS drug discovery lags behind other oncogene targets [3], and only one single KRASG12C inhibitor (sotorasib) was recently approved by the FDA for non-small-cell lung cancer (NSCLC) [10,11].”
BackgroundRekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 7
Park, S. L., Saralamma, V. V. G., Nale, S. D., Kim, C. J., Jo, Y. S., Baig, M. H., & Cho, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28495 · Cited by 7
Zhang, L., Chen, W., Wei, H., & Yu, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13745 · Cited by 6
Song, Z., Li, Z., Zhang, Y., Wang, P., Jiang, L., Zhao, Y., Zhou, J., Wang, X., Zhuang, W., Shi, J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116153 · Cited by 6
Texidor, K., Uyghur, D., Wiese, N., Davis, L. O., Green, M., Sharmen, F., Ijaz, A., Barnes, K. M., Bagett, M., Ye, J., et al. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130572 · Cited by 6
Xia, Y., Zhang, S., Luo, H., Wang, Y., Jiang, Y., Jiang, J., & Yuan, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176157 · Cited by 7
Qiu, Q., Tan, D., Chen, Q., Zhou, R., Zhao, X., Wen, W., Yang, P., Li, J., Gong, Z., Zhang, D., et al. (2024) · American Journal of Cancer Research · doi:10.62347/fssf9938 · Cited by 6
Inci, T. G., Acar, S., & Turgut‐Balik, D. (2024) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2687 · Cited by 6
“Additionally, a few antibodies and Kirsten rat sarcoma (KRAS) inhibitors are used in NSCLC treatment (Figure 2) (Wishart et al., 2018; NIH, 2023 1 ).”
InfluentialSantos, L. M., & da Silveira, N. J. F. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230714163823 · Cited by 5
Cao, H., Huang, Z., Liu, Z., Zhang, X., Ren, Y., Hameed, M. S., Rao, L., Makunga, N. P., Dobrikov, G. M., & Wan, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01886 · Cited by 5
Han, D., Zhou, Y., Zhang, K., Gai, C., Zhang, P., Chai, X., Zhuo, X., Zhao, Q., Zou, Y., & Zhu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117568 · Cited by 5
An overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Han, Z., Wu, Q., Rao, H., Xu, T., & Zhou, C. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130283 · Cited by 5
Exploiting allosteric modulation: a new frontier for precision medicine
Alum, E. U., Udechukwu, C. D., & Obasi, D. C. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10650-9 · Cited by 5
“Sotorasib (AMG 510) is a first-in-class covalent inhibitor targeting the KRAS^G12C mutation, prevalent in various cancers, including non-small cell lung cancer (NSCLC) [ 71].”
Autophagy inhibition enhances sensitivity of alpelisib in PI3K–mutated non-small cell lung cancer
Kim, J., Shrestha, C., Kim, T. W., Lee, S.-B., Lee, G., Jung, D., Hwang, M., Kang, S., Park, H. S., Kim, H., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118620 · Cited by 5
Li, J., Song, N., Ma, R., & Qu, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.118831 · Cited by 5
“Ongoing research involves mutant KRAS inhibitors, including sotorasib and adagrasib, which have received approval for the second-line therapy of advanced non-small cell lung cancer (NSCLC) [13, 14].”
Targeting “undruggable” cancer proteins: pharmacological challenges and emerging strategies
Coelho‐Silva, J. L., Parducci, N. S., Carvalho, M. F. L., Vahedian, V., Lima, K., de Almeida, B. O., & Machado‐Neto, J. A. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1-2830 · Cited by 5
Exploration of Kras Mutations and Their Potential for Being a Target Molecule in Cancer Chemotherapy
Chinthareddy, A., & Oroszi, T. L. (2023) · Journal of Cancer Therapy · doi:10.4236/jct.2023.146022 · Cited by 5
Genetically encodable biosensors for Ras activity
Weeks, R., Mehta, S., & Zhang, J. (2024) · RSC Chemical Biology · doi:10.1039/d3cb00185g · Cited by 5
“61 While this is an important step in treating cancers with mutated Ras, KRasG12C only makes up a fraction of oncogenic Ras mutations.”
BackgroundBrenner, R. J., Landgraf, A. D., Bum‐Erdene, K., González-Gutiérrez, G., & Meroueh, S. O. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00378 · Cited by 5
Exploiting Avidity Effects for the Discovery of Low Affinity Protein-Binding Fragments
Jayalath, I. M., Beckwith, D. M., Yoon, J., Liu, X., & Kodadek, T. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01742 · Cited by 4
Zeng, J., Yin, F., Fan, Y., Zheng, K., Zhang, Z., Liu, L. T., Jiang, R., Li, N., Liu, F., Xia, C., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118565 · Cited by 4
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Ghosh, A., & Fortino, V. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.12.003 · Cited by 4
“Particularly for Sotorasib, it was the first approved inhibitor for KRAS-mutant proteins that have been long held as one of the root causes of cancer (Blair, 2021).”
Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling
Cheng, M., Wu, W., Li, X., Tao, X., Jiang, F., Li, J., Shen, N., Wang, F., Luo, P., He, Q., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02431-x · Cited by 4
Binding Specificity and Local Frustration in Structure-based Drug Discovery
Yan, Z., Li, Y., Cao, Y. J., Tao, X., Wang, J., & Jiang, Y. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673376099250428054846 · Cited by 4
yousif, B. J., Alwahab, D. H. A., Mohammed, H., Yasin, Y. S., & Jumaa, A. H. (2025) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2025.26.8.3053 · Cited by 4
“[55] And mutant RAS, resulting in a docking score of (-6.2) kcal/mol for binding and presenting.”
InfluentialDu, P., Liu, L., Hu, T., & An, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.778035 · Cited by 4
Lu, C., Zou, L., Wang, Q., Sun, M., Shi, T., Shuang, X., Meng, F., & Du, J. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.10431 · Cited by 4
Zhang, Y., Tong, S., & Wan, L. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2499219 · Cited by 3
Xie, C., Ke, J., & Liu, F. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.008 · Cited by 3
Gang, X., Sun, Y., Hao, J., Zhao, S., Wang, Y., Yang, X., Li, H., & Zhao, M. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108930 · Cited by 3
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC
Cavazzoni, A., Mariano, M. P., Palladini, A., Digiacomo, G., Monica, S., Bonelli, M., Galetti, M., Pace, I., Roncarati, R., Giovannetti, E., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108939 · Cited by 3
Go, J., Lee, D., Kim, M., Han, K., Choi, G., Song, C., Ahn, S., Lee, Y., Lee, J.-Y., Wang, Y. P., et al. (2026) · Advanced Science · doi:10.1002/advs.202515654 · Cited by 3
“…HRKs to monitor inhibition of oncogenic KRAS variants in a mutation-specific manner, we assessed their response to two well-characterized KRAS inhibitors: sotora-sib (AMG-510) [ 43 ], a covalent G12C-specific inhibitor, and MRTX1133 [ 44 ], a potent non-covalent compound selectively targeting G12D.”
Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon
Pan, S.-Y., Ye, Y.-H., Zhou, Z., Fan, J., Zhou, J., & Zhou, S. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.44 · Cited by 3
Study of the mass balance, biotransformation, and safety of [14C]IBI351 in healthy Chinese subjects
Wang, S., Lin, W. H., Ahmed, B., Zhong, T., Zhao, J., Xie, L., Feng, H., Chen, J., Zhang, C., Yan, P., et al. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.38.20240254 · Cited by 4
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Luo, B., Liao, M., Nie, B., Yu, Y., & Yao, Q. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-748 · Cited by 3
Megid, R., Ribeiro, G., Gomes, I. N. F., Laus, A. C., Leal, L. F., da Silva, L. S., Ariwoola, A.-B. A., Dias, J. M., Reis, R. M., & Oliveira, R. J. D. S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537523 · Cited by 3
“Notably, sotorasib obtained FDA approval for the treatment of advanced KRAS G12C NSCLC in patients who have previously undergone at least one systemic therapy, according to CodeBreaK100 phase I/II clinical trial (Blair, 2021).”
Liaigre, L., Perrier, Q., Orhon, P., Briault, A., Romand, P., Falque, L., Raymond, C. S., Degano, B., & Bedouch, P. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101678 · Cited by 3
Bao, Y., Jia, F., Li, M., Xu, R., Xie, Y., Zhang, F., & Guo, J. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c08648 · Cited by 3
Cao, Z., Wang, Q., Neumann, H., & Beller, M. (2024) · Angewandte Chemie · doi:10.1002/ange.202410597 · Cited by 3
Bysani, S., Mondal, S., Chakraborty, S., & Killari, K. N. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1145 · Cited by 3
“…Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India the United States Food and Drug Administration (US FDA), as a second-line treatment for locally advanced or metastatic NSCLC containing the KRAS G12C mutation, based on results of phase II clinical trial [3] .”
BackgroundLimited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
Li, H., Liu, C., & Wang, Y. (2022) · Future Oncology · doi:10.2217/fon-2021-1488 · Cited by 3
Ohshima, H., Kobayashi, E., Inaba, M., Nakazawa, R., Hirai, N., Ueno, T., Nakanishi, Y., Endo, K., Kondo, S., Moriyama‐Kita, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073093 · Cited by 2
Methods for Controlling Small GTPase Activity
Faulkner, B. M., He, Y., Sitrin, D., & Stains, C. I. (2025) · ChemBioChem · doi:10.1002/cbic.202500156 · Cited by 2
[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].
Shi, J., Wang, Y., Zheng, J., & Zhou, J. (2025) · PubMed Central · doi:10.3779/j.issn.1009-3419.2025.101.13 · Cited by 2
“…期 NSCLC 患者的 ORR 为 37.1% , mPFS 和 mOS 为 6.8 与 12.5 个月。该药据此获美国食品药品监督管理局( Food and Drug Administration, FDA )批准用于 KRAS G12C 突变 NSCLC 后线治疗 [71] 。 III 期试验(对比多西他赛) [13] 中,索托拉 后相关 [72] 。汇总多项临床试验数据( n =549 )的研究 [73] 显示: 70.7% 的患者发生治疗相关不良事件( treatment-related adverse events, TRAEs ),其中 ≥3 级占…”
InfluentialGomez, M. C., Rajendran, K., & Tayo, L. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-44280-3 · Cited by 2
Csorba, N., Ábrányi‐Balogh, P., Orgován, Z., Szalai, T. V., Ferenczy, G. G., Kollár, L., Péczka, N., Imre, T., Simon, J., Szabó, P. T., et al. (2026) · ChemBioChem · doi:10.1002/cbic.70421 · Cited by 2
A Real-World Study Reporting the Use of Foundation Medicine® Testing in Portugal
Pinto, R., & Schmitt, F. C. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4030014 · Cited by 2
Liu, Y., Tang, S. C., Li, C. H., To, K. F., Li, B., Chan, S. L., Wong, C. H., & Chen, Y. (2024) · Cancer Science · doi:10.1111/cas.16286 · Cited by 2
Klußmann, M., Reuter, J., Werner, C., & Neundorf, I. (2025) · Journal of Peptide Science · doi:10.1002/psc.70009 · Cited by 2
“…Ras-mediated cancer was termed “undruggable” [26, 27], but recently, significant progress has been made in this field as several KRas G12C inhibitors, for example, sotorasib (AMG-510, Amgen) [28, 29], adagrasib (MRTX-849, Mirati) [30, 31], and JNJ-74699157 (ARS-3248, J&J) [32–34], were developed.”
Choi, S., Kim, H., Ryu, W., Choi, K., Kim, T., Song, D., & Han, G. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106234 · Cited by 2
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241264853 · Cited by 2
Shen, S., Zhang, Q., Wang, Y., Chen, H., Gong, S., Liu, Y., Gai, C., Chen, H., Zhu, E., Yang, B. H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185278 · Cited by 2
Zalli, D., Mai, Z., Ferati, E., Ramaj, A., Bregu, R., & Pranjol, M. Z. I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_413 · Cited by 2
Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway
Kim, N., Shin, I., Kim, Y., Jeon, E., Lee, J., Lee, C., Nam, Y., Lee, S., Ju, E., Kim, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.768022 · Cited by 2
Analysis of the Structural Transformations Underlying the Design of Innovative Next-in-Class Drugs
Balakin, K. V. (2023) · Russian Journal of General Chemistry · doi:10.1134/s107036322315001x · Cited by 2
RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis
Donninger, H., Ferrill, R., Baby, B. V., Hobbing, K. R., Dean, W. L., Miriyala, N., Jigo, R., Burlison, J. A., Trent, J. O., Monsen, R., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110809 · Cited by 1
“The approval of the direct KRAS12C inhibitor Sotorasib has been a seminal moment in the RAS field (36).”
Shkil, D. O., Eliseev, I. A., Ivanov, R. A., & Balakin, K. V. (2026) · Russian Chemical Bulletin · doi:10.1007/s11172-026-4863-z · Cited by 1
A chemigenetic endogenous Ras activity biosensor for live-cell pharmacology
Weeks, R., Zhou, D. R., Frei, M. S., & Zhang, J. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02276-0 · Cited by 1
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., et al. (2026) · MedComm · doi:10.1002/mco2.71050 · Cited by 1
“Mechanistically, these agents exploit the unique cysteine residue generated by the G12C substitution and irreversibly bind to the Switch-II pocket, thereby stabilizing KRAS in its inactive GDP-bound state [ 15, 16 ].”
Arun, A. S., Liarakos, D., Mendiratta, G., Kim, J., Goshua, G., Olson, P., & Stites, E. C. (2025) · The Pharmacogenomics Journal · doi:10.1038/s41397-025-00364-3 · Cited by 1
Kandula, J. S., Parmar, K., Priyadharshni, A. R., Kumar, A., & Radhakrishnanand, P. (2025) · Chirality · doi:10.1002/chir.70037 · Cited by 1
Liu, M., Wan, S., Guo, S., Liu, J., Li, W., Wang, L., Li, F., Zhang, J., Liu, X., Liu, D., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00361 · Cited by 1
RAS Inhibitors: Changing the Paradigm from the Undruggable
Campana, F., Bellis, E. D., Porcaro, F., Guida, G. D., Gravara, L. D., Servetto, A., Morgillo, F., Papaccio, F., Filippelli, A., Corte, C. M. D., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070773 · Cited by 1
Research progress of small molecule targeted drugs for non-small cell lung cancer
Qiu, T., & Huang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1847493 · Cited by 1
Yang, P., & Li, Y. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01514-x · Cited by 1
“Representative drugs include sotorasib, adagrasib, and divarasib [9–11].”
Site-directed antibodies targeting driver mutations of the KRAS protein
Li, X., Mendez, Q. M., Chapados, C. D., Acca, F. E., Driscoll, H., Oliveira, J., Liu, J., Jones, K. S., Ferguson, M., Wallace, R. L., et al. (2025) · New Biotechnology · doi:10.1016/j.nbt.2025.04.003 · Cited by 1
Recent Developments, Challenges and Opportunities in Targeting the KRAS Pathway
Pothuganti, M. K., Mitra, S., Iyer, P. S., & Gowda, N. M. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220704104028 · Cited by 2
Metadata
- Authors
- Blair, H. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Blair, Hannah A.
- Venue
- Drugs
- Published
- 2021-08-06
- Volume
- 81
- Issue
- 13
- Pages
- 1573-1579
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8531079
- OpenAlex
- W3193019540
- Cited by
- 241
- References
- 11
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 53 · 2023: 46 · 2022: 53 · 2021: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-10-23)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- sotorasib, KRAS G12C mutation, non-small cell lung cancer, drug approval, accelerated approval, colorectal cancer, solid tumors, drug development milestones
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Piperazines, Pyridines, Pyrimidines, United States, United States Food and Drug Administration, Drug Approval, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

